Significant delay in the introduction of systemic treatment of moderate to severe psoriasis: a prospective multicentre observational study in outpatients from hospital dermatology departments in France

被引:30
|
作者
Maza, A. [1 ]
Richard, M. A. [2 ]
Aubin, F. [3 ]
Ortonne, J. P. [4 ]
Prey, S. [5 ,6 ]
Bachelez, H. [7 ]
Beylot-Barry, M. [5 ,6 ]
Bulai-Livideanu, C. [1 ]
Lahfa, M. [1 ]
Nougue, J. [8 ]
Mengual, X. [9 ]
Le Moigne, M. [1 ]
Lauwers-Cances, V. [10 ]
Paul, C. [1 ]
机构
[1] Univ Toulouse 3, Serv Dermatol, Hop Larrey, UMR CNRS INSERM 1056 5165, F-31062 Toulouse, France
[2] Aix Marseille Univ, UMR 911, Inserm CRO2, F-13385 Marseille, France
[3] Univ Franche Comte, F-25030 Besancon, France
[4] CHU Nice, Hop Archet 2, Serv Dermatol, Nice, France
[5] CHU Bordeaux, EA 2406, Serv Dermatol, F-33000 Bordeaux, France
[6] Univ Bordeaux Segalen, F-33000 Bordeaux, France
[7] Hop St Louis, Serv Dermatol, F-75475 Paris, France
[8] Ctr Hosp Montauban, Serv Dermatol, Montauban, France
[9] Statitec, Labege, France
[10] CHU Toulouse, Serv Epidemiol, Toulouse, France
关键词
PHASE-III TRIAL; PATIENT-MEMBERSHIP SURVEY; QUALITY-OF-LIFE; DOUBLE-BLIND; ALEXITHYMIA; IMPACT; ADALIMUMAB; DEPRESSION; EFFICACY; BURDEN;
D O I
10.1111/j.1365-2133.2012.10991.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background There is a low rate of systemic treatment usage in moderate to severe psoriasis. Objectives The primary objective of the present study was to assess the time period between lack of control of moderate to severe psoriasis with topical treatment or phototherapy as perceived by patients and the medical decision to introduce a systemic treatment. Methods This was a prospective multicentre study, which included patients with moderate to severe psoriasis. A standardized questionnaire was completed by physicians and patients at the time the decision was taken to introduce a systemic treatment. The primary outcome was the duration of uncontrolled psoriasis, as estimated by the patient, prior to the introduction of systemic treatment. Factors associated with a delay in systemic treatment defined as > 2 years of uncontrolled psoriasis were assessed. The agreement between patients and physicians on the duration of uncontrolled psoriasis was estimated. Results The study included 142 patients. The mean age was 48 years, the mean Psoriasis Area and Severity index (PASI) was 18.5 and the mean Dermatology Life Quality Index (DLQI) was 12. The median duration of uncontrolled psoriasis estimated by patients and physicians was 3 years and 2 years, respectively. Factors associated with a delay in the introduction of systemic treatment as assessed by patients were fewer than three physician visits since psoriasis was uncontrolled [odds ratio (OR) 3.05; 95% confidence interval (CI) 1.29-7.21], Hospital Anxiety and Depression (HAD) scale < 10 (OR 2.83; 95% CI 1.19-6.71), continuous psoriasis evolution (OR 2 67; 95% CI 1.12-6.42), low consumption of topical treatment (OR 2.35; 95% CI 1.03-5.34). Conclusions There is a significant delay in the introduction of systemic treatment in moderate to severe psoriasis. Patients with low level anxiety and limited use of healthcare resources appear to be at higher risk of experiencing long delays.
引用
收藏
页码:643 / 648
页数:6
相关论文
共 25 条
  • [12] Abdominal obesity and insulin resistance are significant risk factors for liver fibrosis in a cohort of patients with severe psoriasis: results from a prospective, observational cohort study
    Maybury, C.
    Porter, H.
    Lewis, C.
    Kloczko, E.
    Duckworth, M.
    Dew, T.
    Crook, M.
    Natas, S.
    Miquel, R.
    Wong, T.
    Smith, C.
    Barker, J.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 : 10 - 11
  • [13] REAL WORLD SKIN CLEARANCE RATES FOR BIOLOGIC TREATMENTS IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS: INTERIM RESULTS FROM A LARGE PROSPECTIVE, OBSERVATIONAL STUDY
    Paul, C.
    Bewley, A.
    Girolomoni, G.
    Reich, K.
    Puig, L.
    Lacour, J. P.
    Augustin, M.
    Naldi, L.
    Menter, A. M.
    Wade, S.
    Viswanathan, H. N.
    Palmer, K.
    Klekotka, P.
    Woolley, J. M.
    VALUE IN HEALTH, 2015, 18 (07) : A429 - A429
  • [14] Disease severity, treatment patterns, and quality of life in patients with moderate-to-severe psoriasis routinely managed with systemic treatment: results of the CRYSTAL observational study in Central and Eastern European countries
    Raam, Liisi
    Hartmane, Ilona
    Valiukeviciene, Skaidra
    Karamova, Arfenya E.
    Telegdy, Eniko
    Botev, Ivan
    Marina, Diana
    Rubant, Simone
    Albuquerque, Teotonio
    Constantin, Maria Magdalena
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [15] Real-World Data on Brodalumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: An Observational Study from the Czech Republic BIOREP Registry
    Kojanova, Martina
    Turkova, Barbora
    Gkalpakiotis, Spyridon
    Cetkovska, Petra
    Fialova, Jorga
    Dolezal, Tomas
    Machovcova, Alena
    Apol, Eydna Didriksen
    ADVANCES IN THERAPY, 2024, 41 (10) : 3951 - 3971
  • [16] Improvement in scalp psoriasis and quality of life with apremilast in patients with moderate to severe scalp psoriasis regardless of prior systemic treatment: Results from the phase 3, randomized STYLE study
    Wang, Yao
    Gold, Linda Stein
    Lebwohl, Mark
    Strober, Bruce
    Zhang, Zuoshun
    Van Voorhees, Abby
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB63 - AB63
  • [17] The Safety of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: Analyses from a Prospective, Single-Arm, Multicenter, 12-Week Observational Study
    Li, Ying
    Dang, Lin
    Lv, Chengzhi
    Lin, Bingjiang
    Tao, Juan
    Yu, Nan
    Deng, Ya
    Wang, Huiping
    Kang, Xiaojing
    Qin, Hui
    Chen, Rong
    Li, Jinnan
    Liang, Yunsheng
    Liang, Yanhua
    Shi, Yuling
    DRUG SAFETY, 2024, 47 (07) : 711 - 719
  • [18] Real-world treatment patterns and clinical characteristics in patients with moderate-to-severe systemic lupus erythematosus: an analysis of the SLE Prospective Observational Cohort Study (SPOCS)
    Aringer, Martin
    Arnaud, Laurent
    Furie, Richard A.
    Morand, Eric F.
    Peschken, Christine
    Hoi, Alberta
    Desta, Barnabas
    Hedberg, Jonatan
    Een, Tina Grunfeld
    Sorrentino, Alessandro
    Kielar, Danuta
    Tummala, Raj
    Chen, Stephanie
    Ding, Bo
    LUPUS SCIENCE & MEDICINE, 2025, 12 (01):
  • [19] Treatment persistence in paediatric and adolescent patients with psoriasis followed into young adulthood. From topical to systemic treatment: a prospective, longitudinal, observational cohort study of 448 patients
    Bruins, F. M.
    Bronckers, I. M. G. J.
    Cai, R.
    Groenewoud, J. M. M.
    Krol, M.
    de Jong, E. M. G. J.
    Seyger, M. M. B.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (03) : 464 - 472
  • [20] Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study
    Oliver, R.
    Krueger, J. G.
    Glatt, S.
    Vajjah, P.
    Mistry, C.
    Page, M.
    Edwards, H.
    Garcet, S.
    Li, X.
    Dizier, B.
    Maroof, A.
    Watling, M.
    el Baghdady, A.
    Baeten, D.
    Ionescu, L.
    Shaw, S.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : 652 - 663